Sunshine Biopharma, Inc. (SBFM) Moving Quickly on New Anti-Cancer Drug
When Sunshine Biopharma, a development stage pharmaceutical company focused on cancer treatments, recently announced successful test results for its lead compound, Adva-27a, it represented one of several important milestones being met on the drug’s anticipated fast-track path to approval as a vital weapon in fighting particular forms of aggressive cancers. The latest study measured the ability of Adva-27a to inhibit the activity of Topoisomerase II (Top2) cancer growth enzyme, and results showed that the new drug is an excellent inhibitor, requiring a concentration of only 13.7 micromolar Adva-27a to inhibit 50% of the enzyme’s activity. Topoisomerase II is overproduced in…